2025 年 6 月 30 日医麦客新闻 eMedClub News创新药研发已进入“分化”时代,从跟随(Follow)到引领(First),谁能定义下一个创新,便有可能成为时代洪流下被资源主动选择的优质标的。而这种“被选择”,本身就是一家企业价值的最好注脚!跨国药企(MNC)的动态向来是观察行业趋势一个关键窗口。在第 30 届欧洲血液学会(EHA 2025)年会上,强生公布的 CD20 双靶点 ...
Source Link2025 年 6 月 30 日医麦客新闻 eMedClub News创新药研发已进入“分化”时代,从跟随(Follow)到引领(First),谁能定义下一个创新,便有可能成为时代洪流下被资源主动选择的优质标的。而这种“被选择”,本身就是一家企业价值的最好注脚!跨国药企(MNC)的动态向来是观察行业趋势一个关键窗口。在第 30 届欧洲血液学会(EHA 2025)年会上,强生公布的 CD20 双靶点 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.